Digest Network Come funziona
Network
/
Società
Ka
Non verificato

KalVista Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

88 comunicati stampa

Guarda tutti i comunicati
08/04/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/03/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/03/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/03/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/03/2026
Eventi
Industria
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0